Efficacy of Navelbine (NVB) in non-small cell lung cancer (NSCLC).
Depierre
A
A
CHR/Hôpital Saint-Jacques, Besancon, France.
Lemarie
E
E
Dabouis
G
G
Garnier
G
G
Jacoulet
P
P
Dalphin
J C
JC
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D003248:Constipation / Q000139:chemically induced; D004341:Drug Evaluation; D004361:Drug Tolerance; D005260:Female; D005500:Follow-Up Studies; D005602:France; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009367:Neoplasm Staging; D010292:Paresthesia / Q000139:chemically induced; D012026:Reflex, Stretch / Q000187:drug effects; D012074:Remission Induction; D014747:Vinblastine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077235:Vinorelbine
D000970:Antineoplastic Agents; D014747:Vinblastine; D000077235:Vinorelbine